bpc-157 fda warning letter unapproved drug marketing warning new Content Analysis of US FDA Letters FDA advisory committee votes to

Rx Only

Therapeutic and preventive action profile of BPC-157 in the case of lateral patellar compression In mild conditions, BPC-157 helps eliminate anatomical disorders, including varus deformity of the ankle joint

Elderly patients tend to have a greater frequency of decreased hepatic, renal, or cardiac function, and also have concomitant disease or receiving other drug therapy

Dry eye disorder treatment: In a clinical ocular trial, six patients with non-healing neurotrophic keratitis wounds reported a significant reduction in eye discomfort and completely healed after self-administering 0.1% T4 eye drops 2 to 6 times per day for 28 days [5]